2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year. M&A & deals Synaffix continued to build momentum – Lonza acquired the […]
Replacing the lost function of the pancreas is the “holy grail” of treatments for type 1 diabetes, where the body becomes unable to produce the insulin it needs to regulate blood sugar levels. But the technology to do this has actually been around since the 1960s – it’s just been impractical to use on a […]
Navigating turbulent markets was the theme of the final panel discussion at Optimum Strategic Communications’ 15th Annual Investor Conference. Linden Thomson, fund manager at AXA Investment Managers, Geraldine O’Keeffe, partner at EQT Life Sciences, Naveed Siddiqi, senior partner at Novo Holdings, and Joe Anderson, partner at Sofinnova Partners, formed the panel chaired by Stephen Hansen, […]
‘How can the UK better capitalize on its life sciences prowess?’ was the first panel at Optimum’s 15th Annual Healthcare Conference. Led by Chair Dan Mahony, UK Government Life Sciences Investment Envoy & Chair of BIA, the panel participants brought with them a wealth of experience: Annalisa Jenkins, Non-Executive Director, Genomics England; Allan Marchington, Managing […]
Optimum Strategic Communications celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! Optimism, preparation, and resilience, these were the key takeaways from our wonderful speakers on Wednesday 11 October at the Wellcome Trust. Check out our panel summaries below to learn more or to rediscover […]
